PCI Biotech Holding ASA (LON:0JGL)
London
· Delayed Price · Currency is GBP · Price in NOK 1.620
0.00 (0.00%)
At close: May 27, 2025
PCI Biotech Holding ASA Revenue
In the year 2024, PCI Biotech Holding ASA had annual revenue of 6.74M NOK with 125.25% growth. PCI Biotech Holding ASA had revenue of 3.31M in the half year ending December 31, 2024, with 39.33% growth.
Revenue
6.74M NOK
Revenue Growth
+125.25%
P/S Ratio
10.01
Revenue / Employee
1.30M NOK
Employees
5
Market Cap
4.74M GBP
Revenue Chart
* This company reports financials in NOK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.74M | 3.75M | 125.25% |
| Dec 31, 2023 | 2.99M | -1.76M | -37.05% |
| Dec 31, 2022 | 4.75M | -1.52M | -24.28% |
| Dec 31, 2021 | 6.27M | -1.10M | -14.86% |
| Dec 31, 2020 | 7.37M | -2.02M | -21.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |